BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Baiz D, Dapas B, Farra R, Scaggiante B, Pozzato G, Zanconati F, Fiotti N, Consoloni L, Chiaretti S, Grassi G. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines. World J Gastroenterol 2014; 20(3): 795-803 [PMID: 24574752 DOI: 10.3748/wjg.v20.i3.795]
URL: https://www.wjgnet.com/1007-9327/full/v20/i3/795.htm
Number Citing Articles
1
B. Dapas, S. Dall’Acqua, R. Bulla, C. Agostinis, B. Perissutti, S. Invernizzi, G. Grassi, D. Voinovich. Immunomodulation mediated by a herbal syrup containing a standardized Echinacea root extract: A pilot study in healthy human subjects on cytokine gene expressionPhytomedicine 2014; 21(11): 1406 doi: 10.1016/j.phymed.2014.04.034
2
Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinomaCancer Chemotherapy and Pharmacology 2019; 84(4): 809 doi: 10.1007/s00280-019-03918-y
3
Rossella Farra, Bruna Scaggiante, Chiara Guerra, Gabriele Pozzato, Mario Grassi, Fabrizio Zanconati, Francesca Perrone, Cinzia Ferrari, Francesco Trotta, Gabriele Grassi, Barbara Dapas. Dissecting the role of the elongation factor 1A isoforms in hepatocellular carcinoma cells by liposome-mediated delivery of siRNAsInternational Journal of Pharmaceutics 2017; 525(2): 367 doi: 10.1016/j.ijpharm.2017.02.031
4
Tian-Hao Li, Cheng Qin, Bang-Bo Zhao, Hong-Tao Cao, Xiao-Ying Yang, Yuan-Yang Wang, Ze-Ru Li, Xing-Tong Zhou, Wei-Bin Wang. Identification METTL18 as a Potential Prognosis Biomarker and Associated With Immune Infiltrates in Hepatocellular CarcinomaFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.665192
5
I-Tao Huang, Bijay Dhungel, Ritu Shrestha, Kim R. Bridle, Darrell H. G. Crawford, Aparna Jayachandran, Jason C Steel. Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinomaExpert Opinion on Investigational Drugs 2019; 28(1): 7 doi: 10.1080/13543784.2019.1551359
6
Pihong Li, Xiaoyu Pan, Zhouci Zheng, Yihan Sun, Yifan Han, Jianda Dong. LINC00271 inhibits epithelial-mesenchymal transition of papillary thyroid cancer cells by downregulating trefoil factor 3 expressionAging Pathobiology and Therapeutics 2020; 2(2): 78 doi: 10.31491/APT.2020.06.018
7
Shirley Jusino, Harold I Saavedra. Role of E2Fs and mitotic regulators controlled by E2Fs in the epithelial to mesenchymal transitionExperimental Biology and Medicine 2019; 244(16): 1419 doi: 10.1177/1535370219881360
8
Ying Lü, Jing Zhang, Lei Li, Shun Li, Zongguo Yang. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic reportBioscience Reports 2020; 40(2) doi: 10.1042/BSR20193212
9
N. Halib, M.C.I. Mohd Amin, I. Ahmad, M. Abrami, S. Fiorentino, R. Farra, G. Grassi, F. Musiani, R. Lapasin, M. Grassi. Topological characterization of a bacterial cellulose–acrylic acid polymeric matrixEuropean Journal of Pharmaceutical Sciences 2014; 62: 326 doi: 10.1016/j.ejps.2014.06.004
10
Rossella Farra, Barbara Dapas, Daniele Baiz, Federica Tonon, Sara Chiaretti, Giannino Del Sal, Alessandra Rustighi, Nicola Elvassore, Gabriele Pozzato, Mario Grassi, Gabriele Grassi. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cellsBiochimie 2015; 112: 85 doi: 10.1016/j.biochi.2015.02.015
11
Bruna Scaggiante, Rosella Farra, Barbara Dapas, Gabriele Baj, Gabriele Pozzato, Mario Grassi, Fabrizio Zanconati, Gabriele Grassi. Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effectsInternational Journal of Pharmaceutics 2016; 506(1-2): 268 doi: 10.1016/j.ijpharm.2016.04.031
12
Federica Tonon, Rossella Farra, Cristina Zennaro, Gabriele Pozzato, Nhung Truong, Salvatore Parisi, Flavio Rizzolio, Mario Grassi, Bruna Scaggiante, Fabrizio Zanconati, Deborah Bonazza, Gabriele Grassi, Barbara Dapas. Xenograft Zebrafish Models for the Development of Novel Anti-Hepatocellular Carcinoma MoleculesPharmaceuticals 2021; 14(8): 803 doi: 10.3390/ph14080803
13
Federica Tonon, Cristina Zennaro, Barbara Dapas, Michele Carraro, Massimo Mariotti, Gabriele Grassi. Rapid and cost-effective xenograft hepatocellular carcinoma model in Zebrafish for drug testingInternational Journal of Pharmaceutics 2016; 515(1-2): 583 doi: 10.1016/j.ijpharm.2016.10.070
14
C. Sardo, R. Farra, M. Licciardi, B. Dapas, C. Scialabba, G. Giammona, M. Grassi, G. Grassi, G. Cavallaro. Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery systemEuropean Journal of Pharmaceutical Sciences 2015; 75: 60 doi: 10.1016/j.ejps.2015.03.021
15
Yi Xie, Jing Si, Yu‐Pei Wang, Hong‐Yan Li, Cui‐Xia Di, Jun‐Fang Yan, Yan‐Cheng Ye, Yan‐Shan Zhang, Hong Zhang. E2F is involved in radioresistance of carbon ion induced apoptosis via Bax/caspase 3 signal pathway in human hepatoma cellJournal of Cellular Physiology 2018; 233(2): 1312 doi: 10.1002/jcp.26005
16
Andrea Feliciano, Yoelsis Garcia-Mayea, Luz Jubierre, Cristina Mir, Manuela Hummel, Josep Castellvi, Javier Hernández-Losa, Rosanna Paciucci, Irene Sansano, Yilin Sun, Santiago Ramón y Cajal, Hiroshi Kondon, Aroa Soriano, Miguel Segura, Alex Lyakhovich, Matilde E LLeonart. miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancerCell Death & Disease 2017; 8(10): e3141 doi: 10.1038/cddis.2017.544
17
Jingcheng Wang, Yang Tian, Hui Chen, Hui Li, Shusen Zheng. Key signaling pathways, genes and transcription factors associated with hepatocellular carcinomaMolecular Medicine Reports 2018;  doi: 10.3892/mmr.2018.8871
18
Justin T. Huntington, Xing Tang, Lindsey N. Kent, Carl R. Schmidt, Gustavo Leone. The Spectrum of E2F in Liver Disease-Mediated Regulation in Biology and CancerJournal of Cellular Physiology 2016; 231(7): 1438 doi: 10.1002/jcp.25242
19
G. Cavallaro, M. Licciardi, G. Amato, C. Sardo, G. Giammona, R. Farra, B. Dapas, M. Grassi, G. Grassi. Synthesis and characterization of polyaspartamide copolymers obtained by ATRP for nucleic acid deliveryInternational Journal of Pharmaceutics 2014; 466(1-2): 246 doi: 10.1016/j.ijpharm.2014.03.026
20
Rashmi Nagesh, Rajeshwari H. Patil, M. Naveen Kumar, K.M. Kiran Kumar, Shivaleela Biradar, Babu R. Lamani. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 22022; : 165 doi: 10.1016/B978-0-323-98807-0.00014-4
21
Yan-Jie Chen, Hao Wu, Xi-Zhong Shen. The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapyCancer Letters 2016; 379(2): 245 doi: 10.1016/j.canlet.2015.06.023
22
Margot S. F. Roeten, Jacqueline Cloos, Gerrit Jansen. Positioning of proteasome inhibitors in therapy of solid malignanciesCancer Chemotherapy and Pharmacology 2018; 81(2): 227 doi: 10.1007/s00280-017-3489-0
23
Gennara Cavallaro, Rossella Farra, Emanuela Fabiola Craparo, Carla Sardo, Barbara Porsio, Gaetano Giammona, Francesca Perrone, Mario Grassi, Gabriele Pozzato, Gabriele Grassi, Barbara Dapas. Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cellsInternational Journal of Pharmaceutics 2017; 525(2): 397 doi: 10.1016/j.ijpharm.2017.01.034
24
Shouping Wang, Kun Cao, Yuting Liao, Wei Zhang, Jihua Zheng, Xiaocui Li, Mengting Huang, Yonghao Zhong, Xiao Hu, De Chen, Yanjie Wang. CDCA2 protects against oxidative stress by promoting BRCA1–NRF2 signaling in hepatocellular carcinomaOncogene 2021; 40(25): 4368 doi: 10.1038/s41388-021-01855-w